Document Detail


Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
MedLine Citation:
PMID:  17158945     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Human immunodeficiency virus-infected women (n=16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy.
Authors:
Jashvant D Unadkat; Diane W Wara; Michael D Hughes; Anita A Mathias; Diane T Holland; Mary E Paul; James Connor; Sharon Huang; Bach-Yen Nguyen; D Heather Watts; Lynne M Mofenson; Elizabeth Smith; Paul Deutsch; Kathleen A Kaiser; Ruth E Tuomala
Related Documents :
16374215 - Strategies to prevent mother-to-child transmission of hiv.
20664425 - Primary iliopsoas abscess and pregnancy.
1123815 - Fetal wastage as a consequence of mycoplasma pulmonis infection in mice.
23991275 - Marfan's syndrome and pregnancy: a good maternal and fetal outcome.
22430725 - Body stalk anomaly: adverse maternal outcomes in a series of 21 cases.
17702365 - Outcome of pregnancy in women after pulmonary autograft valve replacement for congenita...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2006-12-11
Journal Detail:
Title:  Antimicrobial agents and chemotherapy     Volume:  51     ISSN:  0066-4804     ISO Abbreviation:  Antimicrob. Agents Chemother.     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-01-22     Completed Date:  2007-06-04     Revised Date:  2013-06-06    
Medline Journal Info:
Nlm Unique ID:  0315061     Medline TA:  Antimicrob Agents Chemother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  783-6     Citation Subset:  IM    
Affiliation:
Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA. jash@u.washington.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cytochrome P-450 CYP3A / metabolism
Female
HIV Infections / drug therapy*
HIV Protease Inhibitors* / adverse effects,  pharmacokinetics
HIV-1*
Humans
Indinavir* / adverse effects,  pharmacokinetics
Infant, Newborn
Liver / metabolism
Male
Maternal-Fetal Exchange
Pregnancy
Pregnancy Complications, Infectious / drug therapy*
Grant Support
ID/Acronym/Agency:
N01-HD-3-3345/HD/NICHD NIH HHS; P50 HD44404/HD/NICHD NIH HHS; U01 AI41089/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/HIV Protease Inhibitors; 150378-17-9/Indinavir; EC 1.14.14.1/Cytochrome P-450 CYP3A
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pse...
Next Document:  Pulmonary endostatin perinatally and in lung injury of the newborn infant.